Please assess the completion status of the following clinical trial:

Trial Title: Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males/females with CDAD~* Females must use adequate contraception~* Signed informed consent~Exclusion Criteria:~* Life-threatening CDAD~* Toxic megacolon~* Pregnant~* Concurrent use of diarrheal agents~* Participation in other trials

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fidaxomicin (Type: EXPERIMENTAL): Participants receiving fidaxomicin 200 mg capsules orally two times daily (every 12 hours \[q12h\] regimen) with intermittent matching placebo to fidaxomicin
- Vancomycin (Type: ACTIVE_COMPARATOR): Participants receiving vancomycin 125 mg capsules orally four times daily (every 6 hours \[q6h\] regimen).

Based on this trial design, predict the completion outcome and termination type (if applicable).